Research Highlights:

  • Electrocardiogram (ECG) measures taken after the first pig-to-human heart transplant found significantly different electrical conduction characteristics compared to those seen in native pig hearts (pig heart transplanted in a pig).
  • Common ECG measures are typically shorter in a pig than in a human, yet, in the Jan. 2022 pig-to-human heart transplant, these ECG measures were unexpectedly prolonged.

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Oct. 31, 2022

DALLAS, Oct. 31, 2022 — Heart rhythm measures in the electrocardiograms of the first pig-to-human heart transplant found unexpected differences in the electrical conduction system of the genetically modified pig heart compared to an unmodified pig heart, according to preliminary research to be presented at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

Xenotransplantation — the process of implanting an organ from one animal species to another — took a leap forward in January 2022, when a 57-year-old man with terminal heart disease received the first-ever transplant of a genetically modified pig heart. The patient lived for 61 days.

Researchers have been working on this new pig-to-human transplantation technique for over 30 years. If successful, harvesting hearts from genetically modified pigs, whose genes have been altered so that they can be safely transplanted to humans, may one day be a reality.

“There are several potential challenges for transplanting a pig heart into a human. With any transplant including this one, there is always the risk of rejection, the potential risk of infection and a third one is abnormal heart rhythms, and that is where the electrocardiogram (ECG) comes in,” said Timm Dickfeld, M.D., Ph.D., a professor of medicine and director of electrophysiology research at the University of Maryland School of Medicine in Baltimore. “It’s truly a novel finding that the ECG parameters of the pig heart after transplantation into a human were so different compared to the commonly found ECG parameters for native pig hearts.”

Monitoring the heart with ECG after transplantation is one way to assess the electrical conduction system after a heart transplant. A 12-lead ECG measures the electrical conduction in 12 different electrical angles of the heart. 

Specifically, researchers reviewed two ECG measures: the PR interval/QRS complex and the QT interval. The PR interval and QRS complex measure the time it takes electricity to travel from the top to the bottom chamber and across the bottom chambers, thus, pumping blood through the heart. The QT interval measures the time it takes the lower chambers of the heart to go through a full electrical cycle associated with a heartbeat.

For this study, the ECG data of the transplant patient were collected usually once a day after the transplant. Prior research demonstrated that ECG parameters of the pig heart in a pig body had a short PR interval (50 to 120 milliseconds), short QRS (70 to 90 milliseconds) and short QT (260 to 380 milliseconds).

“In contrast, the first-ever ECG of a genetically modified heart xenotransplant found a longer PR interval of 190 milliseconds, QRS duration of 138 milliseconds and QT of 538 milliseconds, which is longer than what would be expected from a pig heart in a pig body,” Dickfeld said.

“In a human heart, when those parameters get longer, this can indicate signs of electrical or myocardial disease,” he said. “The pig heart ECG parameters were extended to what we see in a human heart and often the measures even extended beyond what we consider normal in a human heart.”

Additionally, the continual ECG measures indicate that prolonged PR intervals remained stable after the transplant, averaging about 210 milliseconds. QRS duration remained prolonged with about 145 milliseconds, however, these shortened later during the 61-day post-transplant period.

“The QRS duration may prolong when, for example, the muscle and the electrical system itself is diseased, and that is why it takes a long time for electricity to travel from cell to cell and travel from one side of the heart to the other,” Dickfeld said. “In general, we would prefer for this QRS measure not to prolong too much.”

Finally, the study revealed an increased QT duration averaging about 509 milliseconds with dynamic fluctuations. The lowest QT duration was observed on day 14. “In the human heart, the QT duration is correlated with an increased risk of abnormal heart rhythms,” Dickfeld said. “In our patient, it was concerning that the QT measure was prolonged. While we saw some fluctuations, the QT measure remained prolonged during the whole 61 days.”

The researchers believe these findings provide a foundation for future research to better understand the effects of xenotransplantation on the heart’s electrical system and to better prepare for future cases of xenotransplantation.

In 2020 (the most recent data available), the United States recorded the highest number of heart transplants at 3,658 transplantations performed, according to the American Heart Association’s 2022 Heart Disease and Stroke Statistical Update. As of February 2021, 3,515 people were on the waiting list for a heart transplant, and 49 people were on the waiting list for a heart and lung transplant, also according to the update.

“The ultimate goal is that if someone needs a heart, xenotransplantation may be an option,” Dickfeld said. “We need to make xenotransplantation safer and more doable in these challenging areas: rejection, infection, pumping problems and certainly in the area of abnormal electrical signals and heart rhythms.”

The major limitation is that this study is a first-of-its kind in a single patient. Future research will have a better foundation of knowledge on which to build.

“This was a true milestone for research on xenotransplantation, the transplantation of organs from one species to another, in this case from pigs to human. There were a number of key steps that will be fundamental to the success of these operations largely centered around genetic manipulation to reduce organ rejection. Solving the problem of rejection may ultimately lead to use of this method to help numerous patients with advanced heart failure,” said Paul J. Wang, M.D., FAHA, who was not involved in the study, director of the Stanford Cardiac Arrhythmia Service and a professor of medicine and bioengineering at Stanford University, and editor-in-chief of the American Heart Association’s journal Circulation: Arrhythmia and Electrophysiology.

“It will be extremely interesting to understand the factors that affect the changes in the parameters observed comparing the pig-in-pig values vs. the pig-in-human values. We will want to look at factors such as how they reflect rejection and hemodynamic status,” Wang said. “Further analysis of the electrocardiogram including ST-T wave abnormalities may also provide unique insights.”

Co-authors are Calvin Kagan, M.D.; Richard Sandeep Amara, M.D.; Muhammad Haq, M.D.; Muhammad Mohiuddin, M.B.B.S.; Susie N. Hong-Zohlman, M.D.; Manjula Ananthram, M.B.B.S.; Charles C. Hong, M.D., Ph.D.; Vincent Y. See, M.D.; Stephen Shorofsky, M.D., Ph.D., and Bartley Griffith, M.D. Authors’ disclosures are listed in the abstract.

The study authors reported no outside sources of funding.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

The American Heart Association’s Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22. 

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.orgFacebookTwitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173;

John Arnst: 214-706-1060,

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and